Eli Lilly is pushing the boundaries of weight loss science with its latest experimental medication, retatrutide, which has shown staggering results in recent clinical trials. According to data released during a medical conference in Europe and published in the journal Lancet, patients with type 2 diabetes taking the highest dose of the drug lost an average of nearly 50 pounds over 80 weeks. For those starting with a body mass index of 35 or higher, the impact was even more pronounced, with average losses reaching approximately 61 pounds. These figures represent a significant leap forward from previous treatments, leading some experts to suggest that the drug’s efficacy could rival traditional bariatric surgery.
Unlike current market leaders like Wegovy and Zepbound that target a single hormone, retatrutide operates as a triple agonist. It mimics three different gut hormones—GIP, GLP-1, and glucagon—to regulate metabolism more aggressively. While participants also saw improvements in their A1C blood sugar levels, the potent formula came with familiar gastrointestinal hurdles. Many users reported experiencing nausea, diarrhea, constipation, and vomiting throughout the study. Despite these side effects, Lilly remains optimistic about the drug’s trajectory and intends to seek FDA approval by March 2027.
Beyond pure weight loss, Lilly is exploring whether retatrutide can treat other conditions such as obstructive sleep apnea. However, there is also a strategic business play happening behind the scenes regarding how the drug is classified. By filing for approval as a biologic medication rather than a small molecule drug, Lilly could secure twelve years of exclusive sales before biosimilars hit the market. This is significantly longer than the typical five year window for generics and may help protect profit margins in an increasingly competitive landscape where black-market versions of these highly coveted drugs are already appearing.
